Pathogenic genes related to premature ovarian insufficiency and their application

Through whole-exome sequencing analysis and functional experiments, 20 new POI pathogenic genes and mutation sites were screened, solving the problem of limited detection efficiency in the existing technology and achieving high efficiency for premature ovarian insufficiency Screening and diagnosis improve the accuracy of disease prediction.

CN116083559BActive Publication Date: 2024-11-15SHANDONG UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202310062159.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-17
Publication Date
2024-11-15
Estimated Expiration
2043-01-17

AI Technical Summary

Technical Problem

In the prior art, in the detection of early onset ovarian insufficiency (POI) related genes, other pathogenic genes other than known pathogenic genes and pathogenic sites cannot be found, resulting in limited disease prediction and diagnosis efficiency.

Method used

By conducting whole-exome sequencing analysis of the POI cohort with the largest international sample size, 20 new POI pathogenic genes were screened out, and their pathogenicity was verified through functional experiments, including detection of gene mutations and protein modifications. ACMG rating obtains pathogenic or suspected pathogenic mutations and discovers new P/LP mutation sites, such as TP63 gene mutation sites c.1928G>A, c.1937T>C and c.1964G>A, as biomarkers Used for screening, diagnosis and predictive evaluation.

Benefits of technology

The etiology screening, auxiliary diagnosis, detection, monitoring and predictive evaluation of premature ovarian insufficiency has been achieved, the scope of POI pathogenic genes has been expanded, and the accuracy of disease prediction and diagnosis has been improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116083559B_ABST
    Figure CN116083559B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of disease detection and molecular biology technology, and specifically relates to pathogenic genes related to premature ovarian insufficiency and their applications. The present invention screens 20 new POI-associated genes by performing whole exome sequencing analysis on the POI cohort with the largest international sample size, verifies their pathogenicity through functional experiments, and further screens the mutations of existing known POI-associated genes, thereby laying a foundation for the prediction, diagnosis, treatment, genetic etiology analysis and establishment of related genetic models of POI, and therefore has good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of disease detection and molecular biology, and specifically relates to pathogenic genes related to premature ovarian insufficiency and applications thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Premature ovarian insufficiency (POI) refers to ovarian failure in women before the age of 40, mainly manifested by abnormal menstruation (amenorrhea, infrequent or frequent menstruation), elevated gonadotropin levels (FSH>25U / L) and fluctuating decreases in estrogen levels. The incidence rate in women before the age of 40 is 3.7%. In recent years, with the postponement of childbearing age, increased environmental pollution, and prolonged survival with tumors, the incidence of POI has increased significantly. POI not only leads to infertility, but is also prone to multi-system diseases such as osteoporosis, cardiovascular disease, mental and neurological diseases, and tumors, which affect women's physical and mental health.

[0004] The etiology of POI is complex, including genetic factors, autoimmune diseases, infections, environmental factors, and iatrogenic factors. Epidemiological studies have shown that POI has a significant genetic tendency. Studies have confirmed that when the mother's menopause age is before 45 years old, the risk of early menopause or POI in the daughter increases by 6 times (OR, 95% CI: 6.02, 3.4-10.7). Twin studies have also shown that the heritability of menopausal age is as high as 53-71%. Therefore, genetic factors are one of the important pathogenic factors of POI, including chromosomal abnormalities and gene mutations. The previous Sanger sequencing technology was inefficient and costly. In recent years, the development of second-generation sequencing technology has greatly improved the detection efficiency of gene mutations and expanded the pathogenic genes of POI to about 95. However, more than half of POI patients still have unknown etiology, and the contribution of gene mutations in the etiology of POI is seriously underestimated. Mutation detection of POI-related genes in the general population or people at high risk of POI is the key to achieving POI prevention and early intervention.

[0005] Chinese patent document 202010421306.X discloses a female POI susceptibility gene detection kit, covering 9 SNP sites of 4 susceptibility genes for POI in Chinese Han women. Chinese patent document 202010351682.6 discloses a marker combination and detection kit for premature ovarian failure gene detection, detecting a total of 15 SNP sites of premature ovarian failure susceptibility genes. Chinese patent document 202010729479.8 discloses a marker combination for premature ovarian failure gene detection, including 47 SNP sites of 17 genes and primers and detection methods for these SNP sites.

[0006] The POI-related genes included in the above existing technologies are all known POI pathogenic genes, and only detect specific SNP sites, which cannot find other pathogenic genes and pathogenic sites of POI patients, and the efficiency of disease prediction and diagnosis is limited. Therefore, there are still insufficient candidate genes for POI risk prediction and diagnosis. Summary of the invention

[0007] In view of the shortcomings of the prior art, the present invention provides pathogenic genes related to premature ovarian insufficiency and their applications, which are used to screen variant sites related to the onset of POI and can be used to detect, prevent, diagnose or treat POI. Based on the above research results, the present invention is completed.

[0008] Specifically, the present invention relates to the following technical solutions:

[0009] The first aspect of the present invention provides the use of a substance for detecting related genes in the preparation of a product for detecting premature ovarian insufficiency;

[0010] The related genes include ALOX12, BMP6, CPEB1, H1-8, HMMR, HSD17B1, KASH5, LGR4, MCMDC2, MEIOSIN, MST1R, NUP43, PPM1B, PRDM1, RFWD3, SHOC1, SLX4, STRA8, ZAR1 and ZP3.

[0011] Furthermore, the substances for detecting the above-mentioned related genes include but are not limited to substances for detecting the expression level of the above-mentioned genes or gene-encoded proteins, protein modification conditions (including but not limited to methylation, acetylation, phosphorylation, adenylation, ubiquitination, etc.) and gene mutation conditions;

[0012] Furthermore, the substances for detecting the above-mentioned related genes specifically include but are not limited to substances based on mass spectrometry, DNA microarray, sequencing, allele-specific probe hybridization, restriction fragment analysis, oligonucleotide ligation detection, single-stranded conformation polymorphism analysis, and allele-specific amplification detection. Those skilled in the art can adopt appropriate methods according to existing known technologies, which will not be repeated here.

[0013] The present invention discovered the above 20 new POI pathogenic genes by performing whole exome sequencing analysis on the POI cohort with the largest sample size in the world, and verified their pathogenicity through functional experiments. Specifically, by detecting the gene mutations in the above genes, the detected gene mutations were rated by ACMG, thereby obtaining pathogenic or suspected pathogenic (P / LP) mutations.

[0014] Specifically, the specific information of the pathogenic gene and its mutation site is as follows:

[0015]

[0016]

[0017] By detecting the above-mentioned pathogenic genes and their mutations, the (cause) screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation of premature ovarian insufficiency can be achieved. Therefore, the product is a product with the above-mentioned (cause) screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation functions of premature ovarian insufficiency.

[0018] Furthermore, the present invention has discovered new P / LP mutation sites in known POI pathogenic genes through research, which also mediate the occurrence of POI disease. The specific information is as follows:

[0019]

[0020]

[0021]

[0022]

[0023] It is worth mentioning that the present application also discovered for the first time that the TP63 gene mutation sites c.1928G>A, c.1937T>C and c.1964G>A mediate the occurrence of POI. Therefore, the TP63 gene carrying the gene mutation sites c.1928G>A, c.1937T>C, c.1964G>A or the TP63 protein carrying the protein mutation sites p.R643Q, p.L646P, p.R655Q can be used as biomarkers for (cause) screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation of premature ovarian insufficiency, and are therefore also within the scope of protection of the present application.

[0024] In practical applications, the products may be in any existing known forms such as primers, probes, nucleic acid membrane strips, (gene or protein) chips, preparations, kits, instruments, detection devices and equipment. Those skilled in the art can realize the above products based on actual conditions without creative work, so the above products all fall within the protection scope of this application.

[0025] The second aspect of the present invention provides a product for detecting premature ovarian insufficiency, wherein the product comprises a substance for detecting related genes.

[0026] Among them, the substance for detecting related genes is the same as that in the first aspect and will not be described in detail here.

[0027] In short, by detecting the above-mentioned pathogenic genes and their mutations, the (cause) screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation of premature ovarian insufficiency can be achieved. Therefore, the product is a product with the above-mentioned (cause) screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation functions of premature ovarian insufficiency.

[0028] The product may be in any known form such as primers, probes, nucleic acid membrane strips, (gene or protein) chips, preparations, kits, instruments, detection devices and equipment. Those skilled in the art can realize the above products according to actual conditions without creative work, so the above products all fall within the protection scope of this application.

[0029] A third aspect of the present invention provides a system for detecting premature ovarian insufficiency, the system comprising:

[0030] i) an analysis unit, the analysis unit comprising: a detection substance selected from the above-mentioned related genes in a test sample of a subject, and;

[0031] ii) an evaluation unit, the evaluation unit comprising: judging the disease condition of the subject according to the condition of the related gene determined in i).

[0032] The sample to be tested may be a human sample, and more specifically, the sample to be tested includes peripheral blood of a subject.

[0033] The detection substances of the related genes are the same as those in the first aspect above and will not be described in detail here.

[0034] The subject's disease condition includes screening, (auxiliary) diagnosis, detection, monitoring and predictive evaluation of the subject's premature ovarian insufficiency (cause).

[0035] The fourth aspect of the present invention provides the use of the above-mentioned related genes in the preparation of premature ovarian insufficiency and / or screening of premature ovarian insufficiency drugs.

[0036] The premature ovarian insufficiency drug is a drug for preventing and / or treating premature ovarian insufficiency.

[0037] The drug may further include a pharmaceutically acceptable carrier, which may be a buffer, an emulsifier, a suspending agent, a stabilizer, a preservative, an excipient, a filler, a coagulant and a conditioning agent, a surfactant, a dispersant or a defoaming agent.

[0038] The drug may also include a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be a virus, a microcapsule, a liposome, a nanoparticle or a polymer and any combination thereof. The delivery vehicle of the pharmaceutically acceptable carrier may be a liposome, a biocompatible polymer, a lipoprotein, a polypeptide, a polysaccharide, a lipopolysaccharide, an artificial viral envelope, an inorganic particle, and a bacterial or viral, bacteriophage, a clay or plasmid vector.

[0039] The drug can also be used in combination with other drugs for preventing and / or treating premature ovarian insufficiency. Other preventive and / or therapeutic compounds can be administered simultaneously with the main active ingredient, or even administered simultaneously in the same composition.

[0040] The medicine can also be administered separately to other preventive and / or therapeutic compounds in a separate composition or in a dosage form different from the main active ingredient. Partial doses of the main ingredient can be administered simultaneously with other therapeutic compounds, while other doses can be administered separately. In the course of treatment, the dosage of the medicine of the present invention can be adjusted according to the severity of the symptoms, the frequency of recurrence and the physiological response of the treatment regimen.

[0041] The medicine of the present invention can be applied to the body by known means. For example, it can be delivered to the tissue of interest by intravenous systemic delivery or local injection. It can be applied optionally via intravenous, percutaneous, intranasal, mucosal or other delivery methods. Such application can be carried out via single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be applied in the present invention can vary depending on various factors to a great extent, such as target cells, biological types or their tissues, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.

[0042] Beneficial technical effects of one or more of the above technical solutions:

[0043] The above-mentioned technical solution screened out 20 new POI-associated genes by performing whole-exome sequencing analysis on the POI cohort with the largest international sample size, verified their pathogenicity through functional experiments, and further screened the mutations of existing known POI-associated genes, thus laying the foundation for the prediction, diagnosis, treatment of POI, genetic etiology analysis, and establishment of related genetic models, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0045] Figure 1 This is the functional verification result for BLM, HFM1, MSH4, NR5A1, MCM8, MCM9 and RECQL4 gene mutations in Example 1 of the present invention.

[0046] Figure 2 It is a functional verification test for PRDM1, STRA8 and MCMDC2 gene mutations in Example 1 of the present invention, wherein a is a pattern diagram of the location of the PRDM1 gene and mutation, b is a western blot result of overexpressing wild-type and mutant PRDM1 proteins in vitro, c is an immunofluorescence result of wild-type and mutant proteins, reflecting their localization in cells, d is an analysis of the degradation of wild-type and mutant proteins after CHX treatment, e is a pattern diagram of STRA8 gene and mutation, fg is a Minigene verification result for STRA8 mutation, h is an immunofluorescence staining result of wild-type and mutant STRA8 proteins, reflecting their localization in cells, i is a pattern diagram of MCMDC2 gene and mutation, j is a schematic diagram of the GFP reporter system, and k is a flow report diagram and a statistical analysis diagram of the HR repair efficiency detection of wild-type and mutant MCMDC2 proteins.

[0047] Figure 3These are the 20 POI-related genes newly discovered in Example 1 of the present invention, wherein a is 32 genes with significant differences in case-control analysis, of which 12 are known genes and 20 are newly discovered associated genes, and b is the follicular development process in which the 20 new POI-associated genes are located.

[0048] Figure 4 It is the Sanger sequencing verification result of TP63 mutation in POI patients in Example 2 of the present invention, wherein a is the Sanger sequencing result of 9 TP63 mutations in POI patients, and b is the mutation sequencing result of POI patient No. 6 and his parents.

[0049] Figure 5 It is a schematic diagram showing the location of TAp63α mutation sites in Example 2 of the present invention, wherein a is a schematic diagram of the TAp63α protein structure and its mutation sites, and b is a species conservation analysis of four mutation sites located in the TID core region.

[0050] Figure 6 It is the experimental result of TAp63α mutation destroying the protein stability state in Example 2 of the present invention, wherein a is the detection result of wild-type and mutant TAp63α proteins, b is the detection result of wild-type and mutant TAp63α protein conformations, and c is the detection result of the interaction between TAp63αΔTID and WT or mutant TID.

[0051] Figure 7 These are the experimental results of mutant TAp63α inducing cell apoptosis in Example 2 of the present invention, wherein a is the result of luciferase reporter gene detection, b is the result of mutant TAp63α causing increased BAX protein expression, and c is the result of TUNEL experiment.

[0052] Figure 8 is p63 in Example 2 of the present invention + / ΔTID The construction strategy and phenotypic identification results of mice, where a is p63 + / ΔTID Construction strategy and genotype identification of mice, b is p63 + / ΔTID Detection results of p63 protein in mouse ovaries, c is p63 + / ΔTID Mouse phenotype and fertility test results.

[0053] Fig. 9 is p63 in Example 2 of the present invention + / ΔTID POI-like phenotype results of female mice, where a is p63 + / ΔTID The result of premature follicle exhaustion in the female mouse ovary, b is p63 + / ΔTID The result of premature loss of oocytes in the female mouse ovary.

[0054] Fig.10 is p63 in Example 2 of the present invention + / ΔTIDThe results of spontaneous apoptosis in mouse oocytes, where a is the result of Cleaved-PARP1 immunofluorescence staining, and b is the expression detection result of apoptosis-related target genes downstream of p63. DETAILED DESCRIPTION

[0055] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0056] It should be noted that the terms used here are only for describing specific embodiments, and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof. If the experimental methods of specific conditions are not indicated in the following specific embodiments, the conventional methods and conditions of molecular biology in the art are usually followed, and such techniques and conditions are fully explained in the literature. See, for example, Sambrook et al., the techniques and conditions described in "Molecular Cloning: Laboratory Manual", or according to the conditions recommended by the manufacturer.

[0057] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out under conventional conditions or under conditions recommended by the sales company; the materials and reagents used in the examples, unless otherwise specified, can be purchased through commercial channels.

[0058] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0059] Example 1

[0060] In this example, whole exome sequencing analysis was performed on the POI cohort with the largest international sample size, and 20 new POI pathogenic genes were discovered, and their pathogenicity was verified through functional experiments.

[0061] 1. POI patients included:

[0062] The POI cohort of this example included a total of 1030 POI patients, excluding known causes of POI, such as chromosomal abnormalities, autoimmune diseases, ovarian surgery or iatrogenic factors such as chemoradiotherapy, etc., and is currently the idiopathic POI cohort with the largest sample size in the world.

[0063] 2. Control inclusion:

[0064] The whole exome data of 5000 normal people in the database were used.

[0065] 3. Whole exome sequencing and data analysis:

[0066] (1) DNA sample preparation and exome sequencing

[0067] We performed whole exome sequencing on all 1030 POI patients. Genomic DNA of all samples was extracted from EDTA-anticoagulated peripheral blood using QIAamp DNA Blood MiniKit (Qiagen), and 1 ug was used for library preparation. DNA libraries were prepared using AIExome Enrichment Kit V1 (iGeneTech, Beijing, China), and 150 bp-200 bp DNA fragments were sequenced using the NovaSeq platform (Illumina, San Diego, CA). Reads were then aligned to the human genome reference sequence GRCh37 / hg19 using Burrows-Wheeler Aligner MEM. GenomeAnalysis Toolkit (GATK) was used to remove duplicate reads and determine single nucleotide variants (SNVs) and small deletions (dels). The variants screened were annotated using the Ensembl Variant Effect Predictor and RefSeq databases.

[0068] (2) Determination of the list of known pathogenic genes of POI

[0069] POI pathogenic genes were retrieved by searching for articles published up to December 2021 in PubMed and OMIM databases using gene-related terms (such as "gene", "inherited", "mutation" or "variant") combined with POI-related terms (such as "ovarian insufficiency", "ovarian failure", "ovarian dysplasia", "ovarian aging", "ovarian dysfunction", "gonadal failure", "gonadal dysplasia", "reproductive dysfunction" or "hypogonadism", etc.). The genes were required to meet the following conditions: ① Deleterious mutations of the mutation have been found in POI patients in the past; ② The relationship between the gene and the disease has been confirmed by animal models or in vitro experiments, or has strong genetic evidence, such as co-segregation in a large POI pedigree. According to the above requirements, we screened out a total of 95 known POI pathogenic genes, and the relevant phenotypic references for each known POI gene are also listed in the table below.

[0070]

[0071]

[0072]

[0073] (3) Determination of harmfulness of mutations

[0074] The mutations of the above 95 genes found in POI patients were classified according to the ACMG rating: pathogenic (P), suspected pathogenic (LP) and of unknown significance (VUS). Mutations rated as VUS were verified by functional experiments.

[0075] Since BLM, HFM1, MCM8, MCM9, MSH4 and RECQL4 genes are all DNA homologous recombination repair genes, we used the homologous recombination (HR) reporter system to detect the HR efficiency of mutations found in BLM, HFM1, MCM8, MCM9, MSH4 and RECQL4, and found that some mutations can lead to decreased HR efficiency of the protein. According to the ACMG rating, these mutation sites can be upgraded from VUS to LP. Since the NR5A1 gene has transcription factor activity, we used the dual luciferase reporter system to functionally verify the mutations found and found that some mutations can lead to impaired transcriptional activity. The above experiments were repeated three times independently. Error bars represent sem, and numbers represent P values: *P value <0.05. **P value <0.01. ***P value <0.001; ns, not statistically significant ( Figure 1 ).

[0076] According to the results of functional experiments, 108 patients were found to carry 119 P / LP mutation sites of 45 known POI pathogenic genes among 1030 POI patients, accounting for 10.4% (107 / 1030) of the total screened population. The site information is as follows:

[0077]

[0078]

[0079]

[0080]

[0081] (4) Discovery of new POI-associated genes through case-control analysis

[0082] First, we screened 703 candidate genes related to ovarian function from the genome. The specific screening criteria were as follows: 1) The gene is involved in the biological process of folliculogenesis and development; 2) According to the Mouse Genome Informatics (MGI, http: / / www.informatics.jax.org / ) and the International Mouse Phenotype Consortium (https: / / www.mousephenotype.org / ) databases, the deficiency of the gene will lead to damage to the ovarian function of mice; 3) The gene was found to be functionally related to pathways related to ovarian function through in vitro studies or other animal models.

[0083] For the 703 genes screened, we performed burden analysis in 1030 POI patients and 5000 controls, using two models: LoF and D-mis models. The LoF model only included LoF variants (start-loss, canonical splice-site, frameshift, and nonsense). For the D-mis model, multiple algorithms were used to predict the harmfulness of missense variants, and we set six criteria to define D-mis: ① SIFT < 0.05, Polyphen2 > 0.15, and MutationTaster predicted as harmful; ② predicted as "likely pathogenic" by M-CAP; ③ predicted as "harmful" by MetaSVM; ④ REVEL > 0.75; ⑤ CADD > 20; and ⑥ CADD > 10. D-mis determined by different criteria were analyzed in parallel, and their results were compared. The number of alleles in cases and controls was compared using a one-sided Fisher's exact test. Genes with significant mutation enrichment in POI patients were determined according to P < 0.05. (5) Sanger sequencing to verify gene variation

[0084] After the above screening, the suspected pathogenic mutations of the candidate genes were obtained, and the accuracy of the mutations was verified by Sanger sequencing.

[0085] The newly discovered POI pathogenic genes and mutation sites are as follows:

[0086]

[0087]

[0088] 4. Functional verification of harmfulness of new POI-associated gene mutations:

[0089] (1) Verification of pathogenicity of PRDM1 gene mutation

[0090] PRDM1 is a key transcriptional regulator required for the proliferation and migration of primordial germ cells. In this example, three PRDM1 heterozygous mutations were detected, including p.Gly11Valfs*14, p.Tyr622*, and p.Leu776Valfs*19, all of which are loss-of-function mutations. All three mutation carriers developed secondary amenorrhea, and ultrasound showed bilateral ovarian atrophy with almost no residual follicles. We then performed functional experiments to verify the pathogenicity of these three PRDM1 mutations ( Figure 2 a). Western blot experiments showed that mutations p.Gly11Valfs*14 and p.Tyr622* resulted in protein truncation, while p.Leu776Valfs*19 further led to a decrease in protein expression ( Figure 2 b). At the same time, the cell overexpression experiment showed that, unlike the uniform nuclear distribution of the wild-type PRDM1-GFP fusion protein, the mutant protein p.Gly11Valfs*14 was expressed in both the nucleus and the cytoplasm, which was more similar to the pEGFP empty vector group, while the mutant protein p.Tyr622* aggregated in dots, suggesting that the mutant protein may have lost its ability to bind to DNA, resulting in abnormal self-aggregation of the protein ( Figure 2 c). In addition, the ethylene oxide experiment showed that after inhibiting protein synthesis, the degradation rate of the mutant protein p.Leu776Valfs*19 was significantly accelerated, indicating that the mutation caused the stability of PRDM1 protein to decrease ( Figure 2 d). Through the above experiments, it was confirmed that the mutation affected the function of PRDM1 protein, which may affect the proliferation and migration of primordial germ cells, leading to a decrease in ovarian reserve and inducing POI.

[0091] (2) Verification of pathogenicity of STRA8 gene mutation

[0092] STRA8 is a gene that is highly expressed during the prophase of meiosis in germ cells. It can play a transcriptional regulatory role, promote the expression of meiosis-related genes, and then trigger the initiation of meiosis. In this example, a splice site mutation c.258+1G>A ( Figure 2e), while no biallelic loss-of-function mutations were found in the 5000 cases. In addition, no biallelic loss-of-function mutations of this gene were found in any public databases, such as gnomAD, ExAC, and 1000Genomes. This rare mutation carried by POI patients suggests that the STRA8 gene is closely related to POI. Subsequently, we confirmed through Minigene experiments that the mutation c.258+1G>A can cause exon 2 skipping of the STRA8 gene, resulting in an in-frame deletion of 66 amino acids in the most highly conserved region of STRA8 (p.Leu21_Lys86del), which is very important for STRA8 nuclear localization and binding to DNA ( Figure 2 fg). Further immunofluorescence staining showed that STRA8 carrying the p.Leu21_Lys86del mutation was confined to the cytoplasm ( Figure 2 h), which is consistent with the protein localization in the Stra8 N-terminal deletion mouse model. The cytoplasmic localization of STRA8 indicates that its transcriptional activation function has been lost, thereby hindering the initiation of meiosis. Given that Stra8 knockout mice have the phenotype of ovarian atrophy and excessive follicle loss, our findings in POI patients suggest that meiotic abnormalities caused by STRA8 gene mutations can be used as one of the indicators for screening the cause of POI.

[0093] (3) Verification of pathogenicity of MCMDC2 gene mutation

[0094] During meiotic prophase, MCMDC2 promotes the pairing of homologous chromosomes and the formation of recombination complexes. We found that two patients with secondary amenorrhea carried p.Gln229* mutation and p.Ala69Leufs*18 mutation, both of which led to the loss of MCM and AAA-lid, the key functional domains of MCMDC2 ( Figure 2 i). Further homologous recombination (HR) repair efficiency detection based on green fluorescent protein (GFP) found that the HR efficiency of these two mutant proteins in reporter HEK293 cells was only 20% of that of the wild-type protein ( Figure 2 jk), which suggests that both mutants can hinder the progress of meiotic homologous recombination, leading to abnormal oocyte meiosis and oocyte apoptosis.

[0095] (4) Verification of pathogenicity of SHOC1 gene mutation

[0096] During meiotic homologous recombination, SHOC1 is involved in stabilizing recombination intermediates and promoting the formation of crossover and synaptonemal complexes. We found a homozygous frameshift mutation p.Leu78Serfs*10 in a POI patient. The patient had menarche at the age of 17, and soon developed oligomenorrhea and amenorrhea. In addition, we also found four heterozygous loss-of-function mutations: p.Gln48Leufs*3, p.Leu1035Glyfs*28, p.Trp1301*, and c.1939+2T>A. The above mutations can cause abnormal binding of SHOC1 to DNA by destroying the conserved XPF endonuclease-like central domain and the C-terminal helix-hairpin-helix (HhH2) domain, thereby hindering the process of meiotic homologous recombination and inducing oocyte apoptosis.

[0097] (5) Heterozygous loss-of-function mutations in eight meiotic genes

[0098] MEIOSIN is another transcription factor that works with STRA8 to drive the initiation of meiosis. Two variants have been found in MEIOSIN, p.Thr221ProfsTer32 and p.Lys72Ter, which disrupt the HLH and HMG DNA binding domains, respectively, thereby affecting the transcriptional activation of meiotic genes.

[0099] CCDC155 is involved in the rapid movement of chromosomes and homologous pairing during meiosis. The three mutations found in this study, c.876+1G>A, c.1269+2T>A, and p.Arg73ProfsTer42, may cause abnormal binding of CCDC155 to dynein through the loss of a large fragment at the C-terminus of the protein, leading to abnormal chromosome movement.

[0100] CPEB1 promotes the translation of SYCP1 / 3 genes and the progression of meiosis. Large deletions of CPEB1 have been reported in POI patients before, but the evidence for association is insufficient. In this study, we found two short deletions, c.1140_1144+10del and c.1438_1444del (p.Val480Profs*17), which were predicted to lead to abnormal protein recruitment during RNA-protein interaction and ribonucleoprotein complex assembly, resulting in unstable mRNA levels of genes regulating meiosis and folliculogenesis.

[0101] NUP43 is a component of the nuclear complex, and its other subunit NUP107 has been reported to cause ovarian dysplasia through meiotic DNA damage response defects. The three mutations of NUP43, p.Thr214MetfsTer20, p.Arg182Ter, and p.Thr214LeufsTer20, are all located in the conserved WD40 domain and are predicted to impair the stability of the nuclear protein complex and affect ovarian reserve through meiotic abnormalities.

[0102] RFWD3 (FANCW) and SLX4 (FANCP) belong to the Fanconi anemia family genes and are involved in meiosis. The homologous recombination repair process depends on the removal of RPA and RAD51 from DNA damage sites, and the two mutations of RFWD3, p.Thr521TyrfsTer2 and p.Lys263AsnfsTer85, may reduce its interaction with RPA and RAD51. SLX4 is involved in the release of Holliday junctions in the homologous recombination process, and the mutations p.Gln34Ter, p.Arg1465GlnfsTer3 and p.Arg310Ter can cause abnormal release of Holliday junctions by affecting the interaction of SLX4 with other nucleases, thereby hindering the progress of meiosis.

[0103] (6) Loss-of-function mutations found in genes related to follicle development

[0104] HMMR protein interacts with the spindle, affecting granulosa cell division and follicle development. In this study, four HMMR loss-of-function mutations were found: c.1386-2A>C, p.Glu223Ter, c.145+1G>A, and p.Glu143AspfsTer2, which can affect granulosa cell function and inhibit follicle development by preventing HMMR protein from binding to the centrosome.

[0105] HSD17B1 is a key ovarian steroidogenic enzyme that maintains estrogen production and granulosa cell function. This study found that five patients carried four loss-of-function mutations in HSD17B1: c.97+1G>A, c.721-1G>C, p.Glu105Ter, and p.Asp318GlyfsTer3. The above mutations can affect its dehydrogenase activity by destroying the short-chain dehydrogenase / reductase domain, leading to abnormal hormone synthesis and granulosa cell function.

[0106] BMP6 is an ovarian-specific ligand that affects follicular development through multiple mechanisms, including promoting the expression of AMH and FSHR. This study found that two patients carried two loss-of-function mutations: p.Gln158Ter and p.Arg381Ter. Both mutants can inactivate BMP6 activity due to the loss of the C-terminal ligand structure that regulates TGF-β signaling caused by the truncation of the two proteins.

[0107] H1-8 is an oocyte-specific linker histone that is involved in promoting oocyte meiotic maturation and fertilization. The loss-of-function mutations found in POI patients in this study: p.Lys84SerfsTer64 and p.Gly71AlafsTer27 can cause abnormal chromatin condensation function by destroying the histone linker domain of H1-8 protein.

[0108] Mutations in the PPM1B and ALOX12 genes are associated with the age of menarche or natural menopause. Depletion of PPM1B leads to premature cellular senescence through sustained activation of p53 and reduced ovulation in mice. The two loss-of-function mutations we found in POI patients: p.Tyr418Ter and p.Pro215LeufsTer7, may inhibit the dephosphorylation of PPM1B. ALOX12 is a key enzyme in fatty acid lipogenesis and plays a role in ovulation. Three mutations in ALOX12: c.542+1G>A, p.Glu637Ter, and p.Gln269Ter can destroy its lipoxygenase domain, thereby affecting its enzymatic activity.

[0109] MST1R is a surface receptor that affects ovulation by regulating nitric oxide levels and inflammatory responses. A total of seven mutations were detected, including three variants found within the Sema domain that are required for ligand binding, three mutations that affect receptor activation by inhibiting the tyrosine kinase domain, and one frameshift mutation that loses both the Sema and tyrosine kinase domains.

[0110] The functional annotations of the above 20 genes show that they are highly correlated with POI. There is a significant enrichment of loss-of-function mutations in POI patients, which can change their protein levels or biological functions. Among them, the experimental verification of PRDM1, STRA8 and MCMDC2 is an example ( Figure 3 ). These data strongly suggest that these 20 novel genes may be previously unrecognized POI causative genes.

[0111] Example 2

[0112] In this example, whole exome sequencing analysis was performed on 1030 patients with idiopathic POI, and it was found that 11 patients carried 9 TP63 gene heterozygous mutations, and their pathogenicity was verified by functional experiments.

[0113] 1. Research subjects

[0114] 1030 patients with idiopathic POI were collected and their peripheral blood was sampled. This study was approved by the Ethics Committee of the Reproductive Hospital Affiliated to Shandong University, and all subjects signed informed consent. The inclusion and exclusion criteria for the idiopathic POI patients are as follows:

[0115] Inclusion criteria: primary or secondary amenorrhea before the age of 40, and FSH levels > 25 IU / L measured twice with an interval of more than 4 weeks.

[0116] Exclusion criteria: patients with known causes of POI such as chromosomal abnormalities, history of ovarian surgery, history of radiotherapy or chemotherapy, and autoimmune diseases.

[0117] 2. DNA Extraction

[0118] Genomic DNA of all samples was extracted from peripheral blood using DNeasy Blood & Tissue Kit (Qiagen). DNA was quantified using OD measurement (NanoDrop, Thermo Scientific), and 1 μg was used for DNA library preparation.

[0119] 3. Whole exome sequencing and data analysis

[0120] 1 μg of genomic DNA was taken and the DNA library was prepared using AIExome Enrichment Kit V1 (iGeneTech, Beijing, China). Exon capture was performed using the SureSelect Target Enrichment System. The captured exon sequences were sequenced using the NovaSeq platform (Illumina HiSeq). The reads were then compared with the human genome reference sequence GRCh37 / hg19 using the Burrows-Wheeler AlignerMEM software. The Genome Analysis Toolkit (GATK) software was used to remove duplicate reads and screen for SNPs and SNVs. The screened variants were then annotated using the Ensembl Variant Effect Predictor and RefSeq databases.

[0121] 4. Interpretation of pathogenicity of variants

[0122] After the above screening, 9 suspected pathogenic heterozygous mutations of the TP63 gene were found in 11 POI patients. According to the American College of Medical Genetics and Genomics guideline (ACMG), the found mutations were analyzed and classified.

[0123] The amino acids at the nine TP63 gene mutation sites were highly conserved among multiple species, and most mutations were evaluated as possible pathogenic variants. The detailed analysis is shown in Table 1.

[0124] Table 1 Functions of TP63 gene mutations in 11 POI patients

[0125]

[0126] Reference sequence: NM_003722.5; ACMG, American College of Medical Genetics and Genomics guidelines; D, pathogenic; P, pathogenic variant; PD, likely pathogenic; POI, premature ovarian insufficiency; VUS, variant of unknown significance; -, not available or not applicable. A, frequency in the gnomAD or ExAC database; B, mutation pathogenicity assessment after functional experiments.

[0127] 5. Sanger sequencing to verify gene variation

[0128] 9 TP63 gene mutations were verified by Sanger sequencing. Figure 4 a). Among them, Sanger sequencing of the family members of POI patient No. 6 revealed that the mutation c.1964G>A carried by the patient originated from his father ( Figure 4 b).

[0129] 6. In vitro functional verification of mutation pathogenicity

[0130] (1) Pathogenicity analysis of human TAp63α mutations

[0131] The TAp63α mutation sites detected in this example were analyzed. Figure 5As shown in a, the p.S285N and p.T567I mutations are located in the DNA binding domain (DBD) and SAM (sterile alpha motif) domain, respectively. The p.T538A mutation is not in any known functional domain. The remaining six mutations all affect the C-terminal TID, which is essential for the formation of inactive dimers. The frameshift mutation p.Q568fs*3 and the nonsense mutation p.R594* are both located in the SAM domain, resulting in the loss of TID. In addition, four point mutations (p.R643Q, p.L646P, p.R647C, and p.R655Q) are located in the core sequence of TID from R643 to R655 (RFTLRQTISFPPR), which is responsible for binding to TAD ( Figure 5 b) The above analysis suggests that mutations that impair TID may be the cause of POI.

[0132] (2) TAp63α mutation disrupts protein stability

[0133] To further detect the pathogenicity of mutant proteins, we overexpressed wild-type (WT) and mutant TAp63α proteins in SAOS-2 (human osteosarcoma cells). Western blotting experiments showed that WT and four mutant proteins (p.S285N, p.T538A, p.T567I, and p.R655Q) were highly expressed, while other mutant proteins were almost undetectable (p.Q568fs*3 and p.R594*) or their expression levels were significantly reduced (p.R643Q, p.L646P, and p.R647C) ( Figure 6 a). Considering that the active form of TAp63α is difficult to detect due to its high turnover rate, the above results suggest that some of these mutant proteins may be spontaneously activated. Subsequently, to further explore the aggregation state of these mutant proteins, we inhibited their proteasome-dependent degradation by MG132 treatment and performed BN-PAGE analysis. The results showed that all TID-related mutations (p.Q568fs*3, p.R594*, p.R643Q, p.L646P, p.R647C and p.R655Q) formed tetramers, while other mutations (p.S285N, p.T538A and p.T567I) remained in a dimer state ( Figure 6b), indicating that only the mutant protein that affects TID is spontaneously activated. Based on previous studies, we speculated that the four point mutations located in the core sequence of TID may destroy the binding of TAD and TID, thereby changing the dimeric conformation of TAp63α protein. To verify this hypothesis, we co-transfected TAp63αΔTID with plasmids of WT or mutant TID and performed co-immunoprecipitation experiments. The results showed that compared with WT TID, the p.R643Q, p.L646P, p.R647C and p.R655Q mutations of TID significantly reduced its interaction with TAp63αΔTID ( Figure 6 c). The above results indicate that TID-related mutations destroy the inactive dimer conformation of TAp63α and form an activated tetramer.

[0134] (3) TAp63α mutant protein activates cell apoptosis

[0135] We evaluated the transcriptional activity of TAp63α by luciferase reporter gene assay. Compared with WT TAp63α, the six TID-related mutants (p.Q568fs*3, p.R594*, p.R643Q, p.L646P, p.R647C, and p.R655Q) activated the transcription of NOXA, PUMA, and BAX promoter reporter plasmids ( Figure 7 a). In addition, six TID-related mutants resulted in a significant increase in BAX protein expression ( Figure 7 b). At the same time, the proportion of TUNEL-positive cells increased significantly in SAOS-2 cells overexpressing TID-related mutants ( Figure 7 c). The above results indicate that mutations affecting TID spontaneously activate TAp63α, promote the expression of its target genes and induce cell apoptosis, ultimately leading to premature oocyte exhaustion and the occurrence of POI.

[0136] 7. In vivo functional verification of mutation pathogenicity

[0137] (1) Construction of p63 + / ΔTID Mouse Model

[0138] To determine the role of p63 TID in the pathogenesis of POI in vivo, we inserted two nucleotides before TID in exon 14 of the mouse p63 gene to introduce a stop codon and specifically knocked out TID. + / ΔTID The genotype of mice ( Figure 8 a) and p63 at postnatal day 1 (P1) by Western blot + / ΔTID Very low levels of p63 protein were detected in the ovaries of mice, and a large number of oocytes were lost as observed by immunofluorescence staining ( Figure 8 b) Compared with WT mice, adult p63 + / ΔTID No obvious abnormalities were observed in the mice, nor were there significant differences in body weight, but p63 + / ΔTID Male mice are fertile, while females are completely sterile ( Figure 8 c).

[0139] (2)p63 + / ΔTID Female mice show POI-like phenotype

[0140] To determine p63 + / ΔTID Causes of female infertility, detailed analysis of ovarian tissue. 4 months (4M) p63 + / ΔTID The mouse ovaries were significantly reduced. Further HE staining of ovarian tissue sections revealed that the follicles were significantly reduced at P1, almost invisible at P5, and completely disappeared at P21 and 4M ( Fig. 9 a). Further immunofluorescence staining revealed that p63 + / ΔTID Compared with WT mice, the number of oocytes at embryonic day 18.5 was not significantly different, but was reduced to about 40% of that in WT mice at P1. + / ΔTID Mouse oocytes can be seen occasionally at P5, but disappear completely at P10 ( Fig. 9 b) These results indicate that loss of p63 TID leads to rapid oocyte depletion and loss of fertility in mice, phenotypically similar to human POI.

[0141] (3)p63 + / ΔTID Spontaneous apoptosis of mouse oocytes

[0142] To further study p63 + / ΔTID To investigate the molecular mechanism of rapid oocyte loss in mice, we examined the apoptosis of mouse ovaries. Immunofluorescence staining of P1 ovarian sections showed that Cleaved-PARP1-positive oocytes were expressed in p63 + / ΔTID Significant increase in ovaries ( Fig.10 a). At the same time, at P1 p63 + / ΔTID Increased expression of BAX protein was also detected in the ovaries, and the mRNA levels of two apoptosis-related target genes Puma and Noxa downstream of p63 were also significantly increased ( Fig.10 b) These results indicate that loss of p63 TID is sufficient to induce spontaneous apoptosis in oocytes, ultimately leading to premature loss of ovarian function in mice, even in the absence of exogenous insults.

[0143] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Application of substances for detecting mutation sites of related genes in the preparation of products for detecting premature ovarian insufficiency; The related genes include ALOX12, BMP6, CPEB1, H1-8, HMMR, HSD17B1, KASH5, LGR4, MCMDC2, MEIOSIN, MST1R, NUP43, PPM1B, PRDM1, RFWD3, SHOC1, SLX4, STRA8, ZAR1 and ZP3; The specific information of the related genes and their mutation sites are as follows:

2. The use according to claim 1, characterized in that: The substances for detecting the above-mentioned related genes specifically include substances based on mass spectrometry, DNA microarray, sequencing, allele-specific probe hybridization, restriction fragment analysis, oligonucleotide ligation detection, single-stranded conformation polymorphism analysis, and allele-specific amplification detection.

3. The use according to claim 1, characterized in that: The product also includes a substance for detecting the mutation site of the following premature ovarian insufficiency pathogenic gene P / LP, wherein the information of the premature ovarian insufficiency pathogenic gene and mutation site is as follows:

4. The use according to claim 1, characterized in that: The product also includes substances for detecting the TP63 gene mutation sites c.1928G>A, c.1937T>C and c.1964G>A and / or detecting the TP63 protein mutation sites p.R643Q, p.L646P, p.R655Q.

5. The use according to claim 1, characterized in that: The product is a product with the functions of screening, diagnosis, detection, monitoring and predictive evaluation of premature ovarian insufficiency.

6. The use according to claim 5, characterized in that The screening for premature ovarian insufficiency is etiology screening.

7. The use according to claim 5, characterized in that The diagnosis of premature ovarian insufficiency is an auxiliary diagnosis.

8. The use according to claim 5, characterized in that The products are primers, probes, nucleic acid membrane strips, chips, preparations, kits, instruments, detection devices and equipment.

9. The use according to claim 8, characterized in that The chip is a gene or protein chip.

10. A system for detecting premature ovarian insufficiency, characterized in that: The system comprises: i) an analysis unit, the analysis unit comprising: a detection substance for determining a mutation site of a related gene selected from the application according to any one of claims 1 to 9 in a test sample of a subject, and; ii) an evaluation unit, the evaluation unit comprising: judging the disease condition of the subject according to the mutation site of the relevant gene determined in i); Wherein, the sample to be tested is a human sample, and the sample to be tested includes peripheral blood of a subject; The subject's disease condition includes screening, diagnosis, detection, monitoring and predictive evaluation of the subject's premature ovarian insufficiency.

11. The system according to claim 10, characterized in that The screening of premature ovarian insufficiency of the subject is etiology screening.

12. The system according to claim 10, characterized in that The diagnosis of premature ovarian insufficiency of the subject is an auxiliary diagnosis.

Citation Information

Patent Citations

  • Female premature ovarian insufficiency susceptibility gene detection model and detection kit

    CN111549116A

  • Female premature ovarian failure susceptibility gene detection model and detection kit

    CN112266953A

  • Marker composition for premature ovarian failure gene detection and detection kit

    CN111500723A

  • Construction method of gene library for detecting female infertility and kit

    CN114875117A

  • Methods and systems for assessing infertility as a result of declining ovarian reserve and function

    US20170107573A1